Trajan Group Holdings Ltd · ASX:TRJ
Trajan — H1 FY2023 Earnings Presentation
12 slides from Trajan's earnings presentation, Feb 27, 2023
Slide 1: FY23 H1 Financial Results
FY23 H1 FINANCIAL RESULTS Stephen Tomisich CEO and Managing Director 27th February 2023 Science that benefits people 1
Slide 2: Our vision
Respect Integrity Our vision Discipline To enrich personal health through scientific tools and solutions Empowerment Diversity Science that Science thatbenefits people benefits people
Slide 3: Company Overview
Company Overview A business operating at global scale >8000 Products manufactured or sold • Global developer and manufacturer of analytical and life sciences products and • devices enriching human well-being through scientific measurement of biological, food, and environmental samples. Strategy info
Slide 4: Trajan Results Summary
REVENUE BY SEGMENT Trajan Results Summary Analytical products Life Science Solutions Consistent high performance for more than a decade 46% 54% Revenue: Strong Organic Growth: $80.1M up 83.2% PCP ($43.7M). $7.6M, up by 18.6% on PCP ($40.8M REVENUE BY LOCATION v $48.4M). Asia Pacific USA EMEA Normali
Slide 5: FY23 Guidance Upgraded
FY 23 Guidance Upgraded Leveraging opportunities and delivering beyond plan Continued strong revenue growth: • Strong product demand from existing and new customers - best in class and superior products, strong customer relationships and innovation-first approach. UPGRADED UPGRADED • Benefit from gl
Slide 6: Acquisition Program
Acquisition Program Integration on track, contribution growing • Acquired revenues of the acquired businesses are tracking to expectations. • Integration of acquired businesses on or ahead of plan. • Latest acquisition of HDExaminer demonstrating active and diverse program of identifying opportuniti
Slide 7: Operational Status Update
Operational Status Update Focus on strategy execution: Progress on many levels Project Transfer of Continued focus Acquisition M&A More than 30 Neptune additional on developing integrations program active industry remains a high manufacturing and leveraging remains and academic priority as an capabi
Slide 8: HY2023 Detailed Financial Performance
HY2023 Detailed Financial Performance Strong organic growth and acquisitions increased our size and scale Revenue ($m) & Gross Profit Margin^ % Normalised EBITDA ($m) & Normalised* EBITDA Margin % Trajan reported overall revenues for the half-year ended 31 December 2022 of $80.1M (2021: $43.7M), up
Slide 9: HY2023 Segment Breakdown
HY2023 Segment Breakdown Acquisitions elevate underlying business portfolio Analytical Products Life Science Solutions Revenue for the period was $43.2M (up by 49.2% on pcp) and gross profit^ grew by $5.6M (up by 45.2%). Revenue for the period was $36.9M (up by 149.8% on pcp) and gross profit^ grew
Slide 10: HY2023 Cash Summary
HY2023 Cash Summary Growing operating cash flow Commentary A$ million HY2022 HY2023 • Growing operating cash flow (compared to HY22) benefiting from HY2023 earnings growth. Normalised EBITDA* 4.8 10.3 • Increase in net working capital during the half year due to increase in payables ($4.9M) and Inco
Slide 11: Q&A
11 Science that benefits people Q&A Science that benefits people
Slide 12: Disclaimer
Disclaimer The material in this presentation is general background information about Trajan Group Holdings Limited (Trajan) and is current at the date of the presentation, 27 February 2023. The information in the presentation is provided for information purposes only, is in summary form and does not
Trajan Group Holdings — H1 FY2023 Earnings Presentation on 6ix